NASDAQ:ABEO - Abeona Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$13.25 -0.45 (-3.28 %)
(As of 08/17/2018 04:00 PM ET)
Previous Close$13.25
Today's Range$13.00 - $14.25
52-Week Range$7.45 - $22.75
Volume401,347 shs
Average Volume963,713 shs
Market Capitalization$645.72 million
P/E Ratio-20.08
Dividend YieldN/A
Abeona Therapeutics logoAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Receive ABEO News and Ratings via Email

Sign-up to receive the latest news and ratings for ABEO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio21.08
Quick Ratio21.08


Trailing P/E Ratio-20.08
Forward P/E Ratio-18.66
P/E GrowthN/A

Sales & Book Value

Annual Sales$840,000.00
Price / Sales756.20
Cash FlowN/A
Price / CashN/A
Book Value$3.64 per share
Price / Book3.64


EPS (Most Recent Fiscal Year)($0.66)
Net Income$-27,310,000.00
Net Margins-881.74%
Return on Equity-23.02%
Return on Assets-22.02%


Outstanding Shares47,940,000
Market Cap$645.72 million

Abeona Therapeutics (NASDAQ:ABEO) Frequently Asked Questions

What is Abeona Therapeutics' stock symbol?

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

How were Abeona Therapeutics' earnings last quarter?

Abeona Therapeutics Inc (NASDAQ:ABEO) announced its earnings results on Friday, August, 10th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.06. The biopharmaceutical company had revenue of $0.82 million for the quarter, compared to the consensus estimate of $1.81 million. Abeona Therapeutics had a negative net margin of 881.74% and a negative return on equity of 23.02%. View Abeona Therapeutics' Earnings History.

When is Abeona Therapeutics' next earnings date?

Abeona Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, November, 21st 2018. View Earnings Estimates for Abeona Therapeutics.

What price target have analysts set for ABEO?

9 brokerages have issued 1-year target prices for Abeona Therapeutics' shares. Their forecasts range from $23.00 to $36.00. On average, they expect Abeona Therapeutics' share price to reach $29.4444 in the next year. This suggests a possible upside of 122.2% from the stock's current price. View Analyst Price Targets for Abeona Therapeutics.

What is the consensus analysts' recommendation for Abeona Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abeona Therapeutics.

What are Wall Street analysts saying about Abeona Therapeutics stock?

Here are some recent quotes from research analysts about Abeona Therapeutics stock:
  • 1. According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (8/15/2018)
  • 2. Maxim Group analysts commented, "Abeona reported 2Q18 with a net loss of $11.7M. The company ended the period with $120M in cash on the balance sheet and with a current burn rate of $11-12M per quarter has sufficient runway into 2020. We expect multiple data points (catalysts) across the company’s gene therapy platform (Sanfilippo into 2019." (8/10/2018)
  • 3. HC Wainwright analysts commented, "for ABO-202 in Batten Disease; Reiterate Buy Stock Data 04/19/2018 Price $20.05 Exchange NASDAQ Price Target $30.00 52-Week High $22.75 52-Week Low $4.55 Enterprise Value (M) $809.2 Market Cap (M) $947 Public Market Float (M) 24.7 Shares Outstanding (M) 47.2 3 Month Avg Volume 1,230,320 Short Interest (M) 7.59 Balance Sheet Metrics Cash (M) $137.8 Total Debt (M) $0.0 Total Cash/Share $2.92 Book Value/Share $3.63 EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.17) (0.13) (0.18) 2Q (0.20) (0.21) (0.19) 3Q (0.08) (0.13) (0.21) 4Q (0.18) (0.19) (0.22) FY (0.64) (0.66) (0.81) Revenue ($M) Full Year – Dec 2016A 2017A 2018E 1Q 0.2 0.2 0.4 2Q 0.2 0.2 0.4 3Q 0.2 0.2 0.4 4Q 0.3 0.2 0.4 FY 0.9 0.8 1.4 25 20 15 10 5 0 APR-17 AUG-17 DEC-17 APR-18 5 4 3 2 1 0 Vol. (mil) Price Orphan Drug Designation obtained for ABO-202 in Europe." (4/20/2018)

Are investors shorting Abeona Therapeutics?

Abeona Therapeutics saw a decrease in short interest in the month of July. As of July 31st, there was short interest totalling 12,522,920 shares, a decrease of 4.6% from the July 13th total of 13,123,166 shares. Based on an average daily volume of 577,599 shares, the short-interest ratio is currently 21.7 days. Currently, 39.9% of the shares of the company are short sold. View Abeona Therapeutics' Current Options Chain.

Who are some of Abeona Therapeutics' key competitors?

Who are Abeona Therapeutics' key executives?

Abeona Therapeutics' management team includes the folowing people:
  • Mr. Steven H. Rouhandeh, Exec. Chairman (Age 61)
  • Dr. Timothy J. Miller, Pres, Chief Scientific Officer & Director (Age 46)
  • Mr. Jeffrey Blaine Davis, Chief Operating Officer (Age 55)
  • Mr. Carsten Thiel, Chief Exec. Officer (Age 54)
  • Mr. Stephen B. Thompson, Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer (Age 64)

Has Abeona Therapeutics been receiving favorable news coverage?

Media headlines about ABEO stock have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Abeona Therapeutics earned a daily sentiment score of 0.22 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.82 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term. View Recent Headlines for Abeona Therapeutics.

Who are Abeona Therapeutics' major shareholders?

Abeona Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), BlackRock Inc. (4.62%), Millennium Management LLC (2.04%), Nexthera Capital LP (1.32%), PointState Capital LP (1.22%) and Bank of America Corp DE (0.20%). View Institutional Ownership Trends for Abeona Therapeutics.

Which major investors are selling Abeona Therapeutics stock?

ABEO stock was sold by a variety of institutional investors in the last quarter, including Ardsley Advisory Partners. View Insider Buying and Selling for Abeona Therapeutics.

Which major investors are buying Abeona Therapeutics stock?

ABEO stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, PointState Capital LP, BlackRock Inc., Nexthera Capital LP, Bank of America Corp DE, TD Asset Management Inc., Millennium Management LLC and Hikari Power Ltd. View Insider Buying and Selling for Abeona Therapeutics.

How do I buy shares of Abeona Therapeutics?

Shares of ABEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Abeona Therapeutics' stock price today?

One share of ABEO stock can currently be purchased for approximately $13.25.

How big of a company is Abeona Therapeutics?

Abeona Therapeutics has a market capitalization of $645.72 million and generates $840,000.00 in revenue each year. The biopharmaceutical company earns $-27,310,000.00 in net income (profit) each year or ($0.66) on an earnings per share basis. Abeona Therapeutics employs 42 workers across the globe.

How can I contact Abeona Therapeutics?

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The biopharmaceutical company can be reached via phone at 214-665-9495 or via email at [email protected]

MarketBeat Community Rating for Abeona Therapeutics (NASDAQ ABEO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  339 (Vote Outperform)
Underperform Votes:  187 (Vote Underperform)
Total Votes:  526
MarketBeat's community ratings are surveys of what our community members think about Abeona Therapeutics and other stocks. Vote "Outperform" if you believe ABEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.